End-of-life Decision-making Among Young Patients With Advanced Cancer: a Grounded Theory Approach

NCT ID: NCT06551831

Last Updated: 2024-08-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-07-23

Study Completion Date

2025-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this qualitative research is to use grounded theory to explore and describe the thoughts of young advanced cancer patients regarding end-of-life care and how these thoughts influence the related decision-making process.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

End-of-life Decision-making

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Young Patients With Advanced Cancer

1. The patient has a solid tumor.
2. The age at initial cancer diagnosis is between 15 and 39 years.
3. The patient is at least 18 years old at the time of enrollment.
4. The patient has cancer with metastasis, either present at initial diagnosis or occurring after treatment or follow-up.
5. After metastasis, the first-line curative treatment is ineffective.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The patient has a solid tumor.
* The age at initial cancer diagnosis is between 15 and 39 years.
* The patient is at least 18 years old at the time of enrollment.
* The patient has cancer with metastasis, either present at initial diagnosis or occurring after treatment or follow-up.
* After metastasis, the first-line curative treatment is ineffective.

Exclusion Criteria

\- Patients who, for any reason, including severe psychological distress (as determined by the attending physician, psychiatrist, or specialist nurse based on assessments and impressions during routine patient care), cognitive impairment, or physical limitations (such as frailty), are unable to communicate or participate in an interview lasting more than 30 minutes.
Minimum Eligible Age

18 Years

Maximum Eligible Age

39 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Taiwan University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Taiwan University Hospital

Taipei, , Taiwan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Pei-Yu Hsu

Role: CONTACT

+886-23123456 ext. 267940

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Pei-Yu Hsu

Role: primary

+886-23123456 ext. 267940

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

202406142RINE

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.